

Introducing

nu·Q nets

Precision Biomarker Across Acute and Chronic Care.

Understanding NETs and NETosis.

As part of our normal response to a pathogen infection, neutrophils (the main white blood cell) produce a web of decondensed chromatin to trap and kill bacteria, fungi and viruses. These are called neutrophil extracellular traps (NETs).

If the cell dies when NETs are released, this unique form of cell death is called NETosis. NETs released into the blood stream, contain nucleosomes, which can be detected by our Nu.Q® NETs assay – the only analytically validated assay to quantify the level of NETs.

Although NETs play a critical role in our normal immune response, some people have elevated levels of NETs which can lead to tissue damage and, in severe cases, sepsis, organ failure, and death.

Volition

Our biomarker-driven solution, Nu.Q® NETs, enables clinicians and researchers to **anticipate disease, help guide treatment decisions**, and **monitor patients over time**, across both acute and chronic conditions, enabling personalized care.

Nu.Q® NETs in Acute & Chronic Diseases.





● Emerging indications

Clinical Use Cases

Early Detection:
Identify patients at risk for earlier intervention

- Enables earlier intervention
- Supports ED and ICU triage
- Reduces time to treatment

Prediction/Tx Selection:
Risk stratification and therapy optimization

- Predicts severity and organ failure in sepsis
- Guides treatment intensity
- Supports precision critical care

Treatment Monitoring:
Monitor disease progression and response

- Tracks response to therapy
- Enables adaptive management

For published studies using our Nu.Q® NETs assay, please visit volition.com/resources

Emerging Indications

- **Trauma** – Early prediction of thrombotic and inflammatory complications
- **Antiphospholipid Syndrome** – Risk indicator of thrombosis enabling personalized treatment selection and monitoring
- **Hidradenitis Suppurativa** – Early detection of flares supporting long-term patient management; aid treatment selection and response monitoring

"The data from two large independent critical care studies provide compelling evidence that H3.1 nucleosome measurement offers clinicians a practical means of assessing NET formation at the bedside. It's exciting to see evidence emerging not only in other acute diseases but in chronic conditions too."

Dr Andrew Retter, Critical Care Lead, UK and Medical Consultant, Volition

Volition | nu·q nets

We are dedicated to revolutionizing the diagnosis and monitoring of life-altering disease by advancing the science of epigenetics.

Our mission is to save lives and improve outcomes for millions of people and animals worldwide.

Nu.Q® NETs Assay:

- Simple, routine blood test
- Clinically validated in multi-center studies
- The only analytically validated quantitative nucleosome assay currently available.
- CE-marked diagnostic solution; scalable from research to routine care



Potential to:

- Detect NETosis
- Predict disease severity
- Support risk stratification
- Monitor disease progression

Get in touch for more information:

https://volition.com/nu-q-nets

asknu.qnets@volition.com

Date of production: February 2026